Biosimilar Medicines: Cost-Effective Alternatives to Conventional Medicines

In 2018, the global biosimilars market attained a value of $6 billion and is projected to register a 29.6% CAGR during the forecast period. The market is registering growth due to the inexpensive nature of biosimilar drugs, increasing geriatric population, rising research & development (R&D) investment by biopharmaceutical companies and extensive pipeline of biosimilars, and rising prevalence of chronic diseases. Generic equivalents of biologics are referred to as biosimilars. They are highly similar and comparable version of an approved biologic medicine and undergo clinical trials for demonstrating efficacy and safety.

To learn more about this report: https://bit.ly/2J9XVCh

When technology is taken into consideration, the biosimilars market is divided into electrophoresis, monoclonal antibody (mAb), nuclear magnetic resonance, recombinant deoxyribonucleic acid, and bioassays. Out of these, the mAb technology dominated the market during the historical period 2014–2018 and is expected to account for the major share of the market during the forecast period as well. This is because of the increasing utilization of mAbs and technological advancements in the field. The division is further predicted to grow at the fastest pace during the forecast period. 

On the basis of indication, the biosimilars market is categorized into growth hormone deficiency, infectious diseases, chronic diseases, auto-immune diseases, blood-related disorders, rheumatology, oncology, and others (which include metabolic disorders). Out of these, the oncology category held the largest share of the market during the historical period and is further predicted to dominate the market during the forecast period. The primary reason for this is the surging incidence of cancer around the world. As per the World Health Organization (WHO), about one in every six deaths took place because of cancer in 2018.

Browse full report at: https://www.psmarketresearch.com/market-analysis/biosimilars-market

The surging prevalence of chronic diseases is among the major driving factors of the biosimilars market. The growing prevalence of cardiovascular diseases (CVD), neurological diseases, and cancer is resulting in the rising drug requirement and hospitalization rate. For example, according to the WHO, CVDs account for 31% of all deaths around the world; and cancer accounted for 9.6 million deaths globally. People suffering from chronic diseases need regular medications, including biosimilars, for managing their health conditions, which is further driving the growth of the market. 

Hence, the market is being driven by the rising R&D investments and growing prevalence of chronic diseases.

Comments

Post a Comment

Popular posts from this blog

Why is Synthetic Biology Market Advancing Rapidly in North America?

Image
According to the forecast of the market research firm, P&S Intelligence, the global synthetic biology market will grow at an explosive pace in the coming years. The factors propelling the advancement of the market are the soaring geriatric population, advanced and innovative applications of synthetic biology, rising support from several government organizations, ballooning research activities, and surging investments being made in research and development activities pertaining to drug development and drug discovery all over the world.  To learn more about this report:  https://bit.ly/2I3rUew Synthetic biology is basically an interdisciplinary domain that deals with the redesigning and fabrication of various biological components and systems that do not exist in the world around us. This interdisciplinary field focusses on the application of several engineering principles to biology. Synthetic biology helps researchers and healthcare professionals majorly in the study and developme
Read more

How is the Spunbond Nonwoven Fabric Changing the Landscape of Multiple Industries?

Image
Commonly known as spun laid, spunbond nonwoven fabric is produced by the continuous process of fibres spun and can be directed with air streams or can be dispersed directly to a web-like deflector. Spunbond is free of lubricants and it is a non-toxic material. As the spunbond nonwoven fabric is very durable in nature and has beneficial traits, such as high strength and resistance to bacteria, it is being increasingly used in the textile industry.  Additionally, with the soaring sales of diapers, feminine hygiene pants, and toddler training pants, owing to the surging per capita income and growing public awareness about personal hygiene, the demand for spunbond nonwovens is increasing sharply. Moreover, the mushrooming requirement for adult incontinence products, on account of the ballooning population of geriatric people, especially in Germany, Japan, and Italy, is also driving the demand for these fabrics across the globe. According to the United Nations Department of Economic and So
Read more

How Will Rapid Urbanization Propel Lead–Acid Battery Sale?

Image
The global automobile production surged from 52,146,292 units between January 2020 and September 2020 to 57,262,777 units between January 2021 and September 2021, as per the OICA. Furthermore, the IEA estimates that global PHEV car and BEV car stock will grow from 3,346,713 units in 2020 to 16,335,941 units by 2025 and 6,850,327 units in 2020 to 29,626,576 units by 2025, respectively. The increasing adoption of EVs and the burgeoning vehicle demand will, therefore, encourage the use of lead–acid batteries in the upcoming years. Additionally, the accelerating urbanization rate and the ongoing industrial revolution will propel the lead–acid battery market growth in the foreseeable future. The rapid urbanization and industrialization creates will create a huge requirement for power, owing to which households and manufacturing units deploy such energy storage devices in abundance. According to the World Urbanization Prospects: 2018 Revision by the Population Division of the UN, the global
Read more